FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2313110133> ?p ?o ?g. }

• W2313110133 endingPage "16013" @default.
• W2313110133 startingPage "16013" @default.
• W2313110133 abstract "Rituximab is a mouse/human chimeric monoclonal antibody targeted toward CD20. It is efficient as first-line therapy of CD20-positive B-cell malignancies. However, a large fraction of treated patients relapse with rituximab-resistant disease. So far, only modest progress has been made in treatment options for rituximab refractory patients. One of the mechanisms for rituximab resistance involves the upregulation of CD46, which is a key cell surface protein that blocks the activation of complement. We have recently developed a technology that depletes CD46 from the cell surface and thereby sensitizes tumor cells to complement-dependent cytotoxicity. This technology is based on a small recombinant protein, Ad35K++ that binds with high affinity to CD46. In preliminary studies using a 6 × histidinyl tagged protein, we had demonstrated that intravenous Ad35K++ injection in combination with rituximab was safe and increased rituximab-mediated killing of CD20-positive target cells in mice and nonhuman primates (NHPs). The presence of the tag, while allowing for easy purification by Ni-NTA chromatography, has the potential to increase the immunogenicity of the recombinant protein. For clinical application, we therefore developed an Ad35K++ protein without His-tag. In the present study, we performed preclinical studies in two animal species (mice and NHPs) with this protein demonstrating its safety and efficacy. These studies estimated the Ad35K++ dose range and treatment regimen to be used in patients. Furthermore, we showed that intravenous Ad35K++ injection triggers the shedding of the CD46 extracellular domain in xenograft mouse tumor models and in macaques. Shed serum CD46 can be measured in the serum and can potentially be used as a pharmacodynamic marker for monitoring Ad35K++ activity in patient undergoing treatment with this agent. These studies create the basis for an investigational new drug application for the use of Ad35K++ in combination with rituximab in the treatment of patients with B-cell malignancies. Rituximab is a mouse/human chimeric monoclonal antibody targeted toward CD20. It is efficient as first-line therapy of CD20-positive B-cell malignancies. However, a large fraction of treated patients relapse with rituximab-resistant disease. So far, only modest progress has been made in treatment options for rituximab refractory patients. One of the mechanisms for rituximab resistance involves the upregulation of CD46, which is a key cell surface protein that blocks the activation of complement. We have recently developed a technology that depletes CD46 from the cell surface and thereby sensitizes tumor cells to complement-dependent cytotoxicity. This technology is based on a small recombinant protein, Ad35K++ that binds with high affinity to CD46. In preliminary studies using a 6 × histidinyl tagged protein, we had demonstrated that intravenous Ad35K++ injection in combination with rituximab was safe and increased rituximab-mediated killing of CD20-positive target cells in mice and nonhuman primates (NHPs). The presence of the tag, while allowing for easy purification by Ni-NTA chromatography, has the potential to increase the immunogenicity of the recombinant protein. For clinical application, we therefore developed an Ad35K++ protein without His-tag. In the present study, we performed preclinical studies in two animal species (mice and NHPs) with this protein demonstrating its safety and efficacy. These studies estimated the Ad35K++ dose range and treatment regimen to be used in patients. Furthermore, we showed that intravenous Ad35K++ injection triggers the shedding of the CD46 extracellular domain in xenograft mouse tumor models and in macaques. Shed serum CD46 can be measured in the serum and can potentially be used as a pharmacodynamic marker for monitoring Ad35K++ activity in patient undergoing treatment with this agent. These studies create the basis for an investigational new drug application for the use of Ad35K++ in combination with rituximab in the treatment of patients with B-cell malignancies." @default.
• W2313110133 created "2016-06-24" @default.
• W2313110133 creator A5004025497 @default.
• W2313110133 creator A5012809255 @default.
• W2313110133 creator A5029285661 @default.
• W2313110133 creator A5031816529 @default.
• W2313110133 creator A5044435315 @default.
• W2313110133 creator A5051320936 @default.
• W2313110133 creator A5056305765 @default.
• W2313110133 creator A5057049857 @default.
• W2313110133 creator A5058339478 @default.
• W2313110133 creator A5060356656 @default.
• W2313110133 creator A5068414594 @default.
• W2313110133 creator A5072667047 @default.
• W2313110133 creator A5079468607 @default.
• W2313110133 creator A5086796397 @default.
• W2313110133 date "2016-01-01" @default.
• W2313110133 modified "2023-10-14" @default.
• W2313110133 title "Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic" @default.
• W2313110133 cites W103845142 @default.
• W2313110133 cites W1491489363 @default.
• W2313110133 cites W1540368379 @default.
• W2313110133 cites W1822742328 @default.
• W2313110133 cites W1965869797 @default.
• W2313110133 cites W1969194497 @default.
• W2313110133 cites W1971765707 @default.
• W2313110133 cites W1976373355 @default.
• W2313110133 cites W1978306901 @default.
• W2313110133 cites W1981755236 @default.
• W2313110133 cites W1999954189 @default.
• W2313110133 cites W2013670229 @default.
• W2313110133 cites W2014534665 @default.
• W2313110133 cites W2017343452 @default.
• W2313110133 cites W2043373884 @default.
• W2313110133 cites W2050349950 @default.
• W2313110133 cites W2057238269 @default.
• W2313110133 cites W2058015212 @default.
• W2313110133 cites W2066485964 @default.
• W2313110133 cites W2067981408 @default.
• W2313110133 cites W2074185982 @default.
• W2313110133 cites W2083454164 @default.
• W2313110133 cites W2092518756 @default.
• W2313110133 cites W2101014938 @default.
• W2313110133 cites W2108269160 @default.
• W2313110133 cites W2112785451 @default.
• W2313110133 cites W2113685734 @default.
• W2313110133 cites W2115351802 @default.
• W2313110133 cites W2122304523 @default.
• W2313110133 cites W2128903029 @default.
• W2313110133 cites W2132733806 @default.
• W2313110133 cites W2134861285 @default.
• W2313110133 cites W2137348614 @default.
• W2313110133 cites W2139256276 @default.
• W2313110133 cites W2140542285 @default.
• W2313110133 cites W2142563497 @default.
• W2313110133 cites W2143901303 @default.
• W2313110133 cites W2150587745 @default.
• W2313110133 cites W2154643481 @default.
• W2313110133 cites W2156486655 @default.
• W2313110133 cites W2167283284 @default.
• W2313110133 cites W2168648203 @default.
• W2313110133 cites W2169697055 @default.
• W2313110133 cites W2170552969 @default.
• W2313110133 cites W2264636885 @default.
• W2313110133 cites W2598700764 @default.
• W2313110133 cites W60759546 @default.
• W2313110133 doi "https://doi.org/10.1038/mtm.2016.13" @default.
• W2313110133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4813608" @default.
• W2313110133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27069950" @default.
• W2313110133 hasPublicationYear "2016" @default.
• W2313110133 type Work @default.
• W2313110133 sameAs 2313110133 @default.
• W2313110133 citedByCount "10" @default.
• W2313110133 countsByYear W23131101332017 @default.
• W2313110133 countsByYear W23131101332019 @default.
• W2313110133 countsByYear W23131101332021 @default.
• W2313110133 countsByYear W23131101332022 @default.
• W2313110133 countsByYear W23131101332023 @default.
• W2313110133 crossrefType "journal-article" @default.
• W2313110133 hasAuthorship W2313110133A5004025497 @default.
• W2313110133 hasAuthorship W2313110133A5012809255 @default.
• W2313110133 hasAuthorship W2313110133A5029285661 @default.
• W2313110133 hasAuthorship W2313110133A5031816529 @default.
• W2313110133 hasAuthorship W2313110133A5044435315 @default.
• W2313110133 hasAuthorship W2313110133A5051320936 @default.
• W2313110133 hasAuthorship W2313110133A5056305765 @default.
• W2313110133 hasAuthorship W2313110133A5057049857 @default.
• W2313110133 hasAuthorship W2313110133A5058339478 @default.
• W2313110133 hasAuthorship W2313110133A5060356656 @default.
• W2313110133 hasAuthorship W2313110133A5068414594 @default.
• W2313110133 hasAuthorship W2313110133A5072667047 @default.
• W2313110133 hasAuthorship W2313110133A5079468607 @default.
• W2313110133 hasAuthorship W2313110133A5086796397 @default.
• W2313110133 hasBestOaLocation W23131101331 @default.
• W2313110133 hasConcept C104317684 @default.
• W2313110133 hasConcept C111684460 @default.
• W2313110133 hasConcept C112705442 @default.
• W2313110133 hasConcept C115085202 @default.

• next